Mineralys Therapeutics Announces Data Presentation at ACC.25 on Lorundrostat for Uncontrolled Hypertension
RADNOR, PA – Mineralys Therapeutics, a pioneering biopharmaceutical company, recently announced that data from their Phase 2 Advance-HTN trial investigating the efficacy and safety of lorundrostat for treating uncontrolled hypertension (uHTN) and resistant hypertension (rHTN) will be unveiled at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo (ACC.25), taking place in Chicago from March 29-31, 2025. This late-breaking clinical trial session is an opportunity for the scientific community to gain insights into the potential benefits of this innovative therapy.
Background:
Hypertension, or high blood pressure, affects millions of individuals worldwide and is a significant risk factor for cardiovascular diseases, including heart attacks and strokes. The Advance-HTN trial focuses on two patient populations: those with uncontrolled hypertension, whose blood pressure remains elevated despite the use of multiple medications, and those with resistant hypertension, whose blood pressure remains uncontrolled despite receiving optimal doses of three or more antihypertensive medications. Current treatments for these conditions have limitations, making the development of new, effective therapies crucial.
The Role of Lorundrostat:
Lorundrostat is an investigational, selective mineralocorticoid receptor antagonist (MRA) designed to target aldosterone, a hormone that plays a critical role in regulating sodium and water balance and blood pressure. By blocking the mineralocorticoid receptors, lorundrostat aims to reduce the production of aldosterone and ultimately decrease blood pressure. Mineralys Therapeutics believes that targeting aldosterone could offer a more effective and targeted approach for treating hypertension and its complications.
Impact on Patients:
For individuals with uncontrolled or resistant hypertension, the potential benefits of lorundrostat could mean improved cardiovascular health and a reduced risk of complications. According to Mineralys Therapeutics, the Phase 2 Advance-HTN trial demonstrated that lorundrostat significantly reduced blood pressure in both patient populations. The presentation at ACC.25 is expected to provide further details on these findings, including data on safety, tolerability, and potential long-term benefits.
Global Implications:
The presentation of the Advance-HTN trial data at ACC.25 could have significant implications for the global healthcare community. Hypertension is a prevalent condition, and current treatments may not effectively address the needs of all patients. If lorundrostat proves to be an effective and safe therapy, it could represent a significant advancement in the treatment of uncontrolled and resistant hypertension. This, in turn, could lead to improved patient outcomes and reduced healthcare costs associated with cardiovascular complications.
Conclusion:
The upcoming presentation of data from the Phase 2 Advance-HTN trial at the American College of Cardiology’s Annual Scientific Session & Expo offers an exciting glimpse into the potential benefits of lorundrostat for the treatment of uncontrolled and resistant hypertension. The innovative approach of targeting aldosterone could result in improved patient outcomes, reduced healthcare costs, and a significant impact on the global healthcare landscape. Stay tuned for further details on this promising therapy.
- Mineralys Therapeutics to Present Data on Lorundrostat for Uncontrolled Hypertension at ACC.25
- Lorundrostat is an investigational MRA targeting aldosterone production
- Data from Phase 2 Advance-HTN trial to be presented at ACC.25
- Lorundrostat could offer improved cardiovascular health and reduced risk of complications for patients with uncontrolled or resistant hypertension
- Potential global implications include improved patient outcomes and reduced healthcare costs
